March 1, 2019 10:54 AM EST

The EMA officially vacates its London HQ — next stop Amsterdam; CHMP backs approval of 8 drugs

Natalie Grover

Reporter

→ The EMA officially said goodbye to its Canary Wharf headquarters in London on Friday, to set up shop in Amsterdam — a decision triggered …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The EMA officially vacates its London HQ — next stop Amsterdam; CHMP backs approval of 8 drugs

Natalie Grover

Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

The EMA of­fi­cial­ly va­cates its Lon­don HQ — next stop Am­s­ter­dam; CHMP backs ap­proval of 8 drugs

Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

The EMA officially vacates its London HQ — next stop Amsterdam; CHMP backs approval of 8 drugs